Green tea ingredient plus trastuzumab fight cancer
the ONA take:
According to findings published online in the journal Nature Nanotechnology, researchers have found that the molecule (-)-epigallocatechin-3-O-gallate (EGCG), which is a major ingredient in green tea, can be utilized as a carrier for anticancer antibodies. EGCG functions as a carrier by binding to the antibody, thereby forming a stable therapeutic nanocomplex.
The researchers used EGCG, which also has anticancer effects, as a carrier for trastuzumab (Herceptin), a common treatment for human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The researchers then injected the EGCG-trastuzumab nanocomplex into mice and observed increased tumor selectivity and decreased tumor growth. In addition, they found that the trastuzumab lasted longer in the blood when part of the nanocomplex compared with when injected alone.
The study only used EGCG for the study, not green tea. Green tea is believed to have numerous antioxidants that may protect against cancer. Future studies could be conducted to determine if drinking green tea while receiving cancer treatment would improve outcomes.
The molecule EGCG in green tea can be utilized as a carrier for anticancer antibodies.
A molecule that is a major ingredient in green tea can be used as a carrier for anticancer proteins, forming a stable and effective therapeutic nanocomplex. These findings, reported in a paper published online this week in Nature Nanotechnology, could help to build better drug-delivery systems. Some cancer treatments depend on medication comprising the therapeutic drug and a carrier that delivers the drug to the tumour site.
When designing drug carriers, several factors must be considered, for example, it must be specific so that it only attacks the tumour. Also, the drug-to-carrier ratio is important because using high quantities of the carrier could result in toxicity if the body cannot metabolize it. Furthermore, the complex will be ineffective if the body attacks and eliminates it too quickly.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|